Investor Overview

December 2023 ProSomnus, Inc. (Nasdaq: OSA)





DISCLAIMER

This presentation is for informational purposes only and should not be relied on for any other purpose. All information provided is as of the date of this presentation unless otherwise noted and ProSomnus assumes no obligation to update the information in this presentation except as required by law.

Certain industry and market data used in this presentation have been obtained from third-party industry sources as well as from research reports prepared for other purposes. ProSomnus has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy and completeness. All of the market data in the presentation involves a number of assumptions and limitations, and there can be no guarantee as to the reasonableness or reliability of such assumptions. ProSomnus assumes no obligation to update the information in this presentation.

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Statements that are not historical facts, including statements regarding ProSomus's expected financial and stock performance. ProSomnus's labeling expansion, the timing and impact of its ongoing clinical studies, its future growth and expenses, the plans and capabilities regarding a remote monitoring program, and the growing markets for its devices, are forward-looking statements. Forward-looking statements also include discussions of strategy, financial projections, guidance and estimates (including their underlying assumptions), statements regarding plans, objectives, expectations, or consequences of various transactions or, and statements about our future performance, operations, products, and services, and should be viewed with caution. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "potential," "projects," "projects," "continue," or "should," or, in each case, their negative or other variations or comparable terminology. The forward-looking statements contained in this presentation are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements are neither statements of historical or current fact nor are they guarantees of future performance. Further, these forward-looking assumptions about general economic, market, industry and operational factors) and changes in circumstances, many of which are beyond our control, difficult to predict as to timing, extent, likelihood, and degree of occurrence, and could cause the actual results to vary materially from those indicated or anticipat

Such risks and uncertainties include, but are not limited to:(i) uncertainty of the projected financial information with respect to ProSomnus's limited operating history and history of losses; (iii) ProSomnus's ability to maintain and grow its profit margin from sales of ProSomnus oral devices; (iv) ProSomnus's ability to expand internationally; (v) the roll-out of ProSomnus's business and the timing of expected business milestones; (vi) ProSomnus's ability to formulate, implement and modify effective sales, marketing, and strategic initiatives to drive revenue growth; (vii) expectations concerning the effectiveness of OSA treatment using ProSomnus oral devices and the potential for patient relapse after completion of treatment; (viii) the understanding and adoption by dentists and other healthcare professionals of ProSomnus oral devices for mild-to-moderate OSA; (ix) risk related to compliance debt covenants or successfully renegotiating such covenants; (x) ProSomnus's ability to obtain additional funding and the risk of potential future significant dilution to stockholders resulting from any such financing or from lender conversions under the convertible debt financing; (xi) the viability of ProSomnus's ability to obtain applicable regulatory approvals and comply with government regulations, including under healthcare laws and the rules and regulations of the U.S. Food and Drug Administration; (xii) the risk of downturns in the market and ProSomnus's industry including, but not limited to, as a result of the COVID-19 pandemic; and (xiv) the outcome of any legal proceedings that may be instituted against ProSomnus.

A further list and description of risks and uncertainties can be found in ProSomnus's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") and any subsequently filed quarterly reports on Form 10-Q, and other documents that ProSomnus may file or furnish with the SEC, which you are encouraged to read and are available on the SEC's website at http://www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Forward-looking statements do not represent our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.

Trademarks

ProSomnus may own or have rights to various trademarks, service marks and trade names that it uses in connection with the operation of its business. This presentation may also contain trademarks, service marks, trade names and copyrights of third parties, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this presentation is not intended to, and does not, imply a relationship with ProSomnus, or an endorsement or sponsorship by or of ProSomnus. Solely for convenience, the trademarks, service marks, trade names and copyrights referred to in this presentation may appear without the TM, SM, [®] or [©] symbols, but such references are not intended to indicate, in any way, that ProSomnus will not assert, to the fullest extent under applicable law, its rights or the right of the applicable licensor to these trademarks, service marks, trade names and copyrights.



ProSomnus Overview

ProSomnus is the leading non-CPAP OSA Therapy

"Sleep Apnea (OSA) is a major public health epidemic" - CDC

\$2.2 Billion immediate opportunity for non-CPAP Therapy (U.S.)

Differentiation and Efficacy: 47% Better Mechanisms of Action

2x More Effective than CPAP in Intent to Treat - FLOSAT

Scientific Data: 17 published + 3 presented studies - >1,500 patients

Market Access: Broad reimbursement coverage U.S. and Europe

Commercial Momentum: TTM \$25.6M, 42.6% Growth vs PY



ProSomnus EVO Precision Medical Device

ProSomnus: The Leading Non- CPAP OSA Treatment

Vision: the leading OSA treatment


- Excellent commercial growth
 - Seven (7) quarters of sequential growth
 - Q3-23 Revenue of **\$7.1M up 41% y/y**
 - YTD Q3-23 Revenue of \$19.8M up 46% y/y
 - Prior Year FY2022 Revenue of \$19.4M up 38% Y/Y
- ProSomnus devices have scientifically demonstrated 90%+ efficacy
- Next-generation sensor device featuring real time remote monitoring of hypoxic burden is approaching commercialization (2024)
- Head-to-head study vs CPAP, preliminary data presented in Aug 2023
- Pursuing label expansion for Severe OSA (2024)
- \$10M financing closed in September 2023
- Global HQ and Manufacturing in Pleasanton, CA
- Highly experienced management team






Sleep Apnea (OSA) is a Major Public Health Epidemic – CDC


OSA is Recurrent Airway Obstruction, Depriving Vital Organs of Oxygen



1 Billion People Worldwide and 75 Million in the US Have OSA, >80% Undiagnosed (Lancet)



Comorbidities of OSA




Source: Frost & Sullivan; Heart Rhythm Society; Davis et al, Early diagnosis and treatment of obstructive sleep apnea after stroke, 2013, Neurology Clinical Practice. Percentages shown represent the prevalence of sleep apnea in patients with the stated medical condition. Prevalence data on graphic available https://fryedental.com/services-sleep-apnea/with Statistical Support: https://dreamsleep.rest/resources/



Significant Public Health Consequences for Un-/Under- treated OSA

OSA is a key predictor of early mortality

OSA All-Cause Mortality (Wisconsin Sleep Cohort) (1)



Source: (1) Young et al, Sleep, 2008 August 1; 31(8): 1071-1078, (2) Academy of Sleep Medicine (2016).


Quality of Life Consequences⁽²⁾

- Sleep Divorce
- Professional Performance
 - Workplace productivity (\$86.9B)
 - Accidents (\$6.5B)
 - Absenteeism
- Driving / Motor Vehicle (\$26.2B)
- Combat Readiness (US Armed Forces)
- Academic Performance
- Untreated Cost per Patient 3x vs Treated



Immediate Opportunity


CPAP: Incumbent Therapy



Issue: >50% Terminate CPAP Usage(1)

Actionable non-CPAP therapy market opportunity of \$2.2 billion in U.S.

1 Billion People Worldwide Have Undiagnosed OSA (Lancet 2019)




(1) Pépin JL, Bailly S, Rinder P, Adler D, Szeftel D, Malhotra A, Cistulli PA, Benjafield A, Lavergne F, Josseran A, Tamisier R, Hornus P, On Behalf Of The medXcloud Group. CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. J Clin Med. 2021 Mar 1;10(5):936. doi: 10.3390/jcm10050936. PMID: 33804319; PMCID: PMC7957656 (2)Peppard, PE, Tyoung, M Palta, EW Hagen, abd KM Hla. "Increased Prevalence of Sleep-disordered Breathing in Adults" American Journal of Epidemiology (2013): National Center for Biotechnology Information. U.S. National Library of Medicine




ProSomnus EVO Personalized Medical Devices

Proprietary Device Design and Personalization Drives Improved Patient Outcomes



Mechanism of Action: EVO repositions and stabilizes the jaw to reduce airway collapse



ProSomnus' ability to <u>comfortably</u> and safely reposition, stabilize and titrate each patient's mandible with <u>sub-millimeter precision</u> reduces airway collapse.



ProSomnus Devices are ~47% Better at Performing the Mechanism of Action for Oral Appliance Therapy


Mechanisms of Action (to Reduce Airway Collapsibility)***	Traditional OAT Devices*	ProSomnus Precision OAT Devices*	Difference*
a) Reposition the Mandible	+/- 3.7mm	+/2mm	+/- 3.3mm
b) Stabilize the Mandible	+/- 1.8mm	+/1mm	+/- 1.9mm
c) Titrate the Mandible	+/- 0.5mm	+/1mm	+/- 0.4mm
Total	+/- 6.0mm	+/4mm	+/- 5.6mm
Implied Efficacy Variance**	50%	3%	47%
* Based on Hu et al, AADSM, 2021			
** 1mm variance equals 8.4% efficacy. Based	' on Kato 2000, Esaki 199	97, Gindre 2008, Aarab 2010	and Walker 2003.

*** Based on AADSM Definition of an Efficacious Oral Appliance, CMS Coding, FDA Guidance, AASM Guidelines

ProSomnus precision technologies enable better and more consistent efficacy



ProSomnus Devices Reposition, Stabilize & Titrate the Jaw to Open the Airway



Total Airway Volume No device = 135cc's With ProSomnus 202 cc's Improvement +50%

Minimum Cross Section No device = 129mm^2 W/ ProSomnus 269.9 mm^2 Improvement +120%




ProSomnus Devices Demonstrate Excellent Efficacy

Clinical results including 17 published & 3 presented studies with >1,500 total patients differentiate ProSomnus from incumbent treatments

Study Design and Key Results

- 33 patients suffering from mild / moderate OSA
- Success goal: Oxygen Desaturation Index (ODI) < 10 events per hour
- ProSomnus success rate 94% vs ~50% for CPAP
- 97% reported significant reduction in snoring
- Excellent safety profile




18 mild, 15 moderate patient types.

Source: Senders et. al., 2003, The surgical treatment of obstructive sleep apnea; Mosca EV, Bruehlmann S, Zouboules SM, et al. In-home mandibular repositioning during sleep using MATRx plus predicts outcome and efficacious positioning for oral appliance treatment of obstructive sleep apnea. J Clin Sleep Med. 2022;18(3):911–919; https://clinicaltrials.gov/ct2/show/NCT03217383.

94% Successfully Treated with ProSomnus


Recent Data



(1) Excerpt from 8/11/2023 Presentation by Dr. Olivier Vanderveken "Comparison of clinical effectiveness and patients' preference for two noninvasive treatment options for patients diagnosed with moderate to severe obstructive sleep apnea: the FLOSAT study"

93% Success Treating OSA to SAS-HB < 60 (n = 152) $^{(2)}$

Figure 1. Individual Responses to Precision Oral Appliance Therapy



(2) Excerpt Mosca et al from CHEST lecture, October 2023 Assessing Precision Oral Appliance Efficacy Using Frequency-Based and Risk-Based Indices SAS-HB = Sleep Apnea Specific Hypoxic Burden



Growing Portfolio of Peer Reviewed Clinical Data

Study	Study Sample		Кеу	
Name	Size	Classification	Finding	
Military 3	360	Independent	Improved Quality of Life	
Military 1	288	Independent	88.1% success for all severities	
San Diego Registry	211	Independent	AHI and ESS Improved	
Syracuse	115	Independent	91% success for mild/moderate	
NOTUS3	58	Independent	94% success for mild/moderate	
Multi-Center	55	Company Supported	98% success for mild/moderate	
Detroit Registry	50	Independent	92% success for mild/moderate	
NOTUS2	48	Independent	90% success for mild/moderate	
Multicenter preference	31	Company Supported	100% preferred	
EFFECTS Study	28	Company Supported	93.6% compliance	
Alaska 3	26	Independent	62% improvement	
Military 2	24	Independent	87.5% success for all severities	
Carlton Study	20	Independent	75% improvement	
UoP	18	Independent	No change in teeth/bite	
India	10	Independent	No change in teeth/bite	
Alaska 2	8	Company Supported	87.9% compliance	
Alaska 1	7	Company Supported	71% improvement	
Syracuse	91	Company Supported	89% success all severities (AHI<10)	
Total Patients	1,448			

Clinical results demonstrate ProSomnus's ability to provide improved patient outcomes

- 17 Clinical Studies featured in peer reviewed publications demonstrating strong:
 - Efficacy
 - >90% (mild/moderate)
 - >87% (all severities)
 - >97% (snoring)
 - Patient Compliance
 - ~90%
 - Safety
 - ProSomnus precision intraoral devices did not demonstrate the types of unwanted tooth movements and bite changes that have been reported in the literature with CPAP and legacy dental products
 - Patient Preference
 - 100%
- 3 Conference podium presentations and abstracts
- >1,500 Patients in published & presented studies



See Appendix for complete clinical study citations.


Excellent Reimbursement Coverage in the U.S. and Key European Markets

Strong reimbursement coverage in the U.S. and Europe provides ProSomnus with attractive economics

- Covered by Medicare and nearly all private U.S. medical insurance
 - CPT codes E0486 & K1027
 - >200 million covered lives
- Robust international coverage
 - Germany, GKV
 - UK, NHS
 - France, Social Insurance
 - Netherlands, Zorginstituut
 - ... and more ...




Patient Journey



Multiple Meaningful Growth Catalysts

Significant value-creating catalysts




Reimbursed OSA Remote Monitoring Platform – Potential Game Changer

Unique ability to monitor efficacy, compliance and health has potential to make ProSomnus front line therapy vs alternate therapy

Sensor Device





Expected commercial introduction 2024

Existing remote patient monitoring reimbursement codes have the potential to create compelling economics and scalable disease management



Data

Patient App


Healthcare Provider Portal

	2				۹ ۵
10000000000000000000000000000000000000	Farm J. Dans Partiel 2. Overview				
O Data Parel -	Overview				
Oversee					
Deptored	All Users	Testay	This week This moreh	7his year 04/08/2021	- 04/08/2025
O Heath Tracking					
A. Manage Usar	Active Users ©		Total Users O		
8. Manage Organizations	3,324	_	10,846		
Ø Serroy					
	Week +5.47%. Day +5.47% 0.00.	25.66	Triek +5.67%	Day +5.475 0.00	354
	User Group	Table	This week This month	This year 04/08/2021	- 04/09/2021
	Group Line : JA Chinae A. Onnial D. 25	and C Group D Group E			(Linus
	Group A -	Group B		Group C	
	1,332	2,332		4,332	
	Gebe 20.22%	Drive 82375	_	Grave 80.22%	_
	8000	800		1000	-
	100 EX.	test (21.02	area -	

- Monitoring of physiologic parameters that are highly predictive of health risks
- Sleep Apnea Specific Hypoxic Burden
- Sleep Apnea Specific Pulse Rate Variability



Strong Record of Top-Line Growth



- Seven (7) quarters of sequential growth
- Q3-23 Revenue \$7.1M up 41% y/y
- YTD Q3-23 Revenue \$19.8M up 46% y/y
- FY2022 Revenue \$19.4M up 38% Y/Y
- Post Market Surveillance
 - > 99% Customer Retention
 - > 99% Would Recommend ProSomnus
 - > 98% Overall and Patient Satisfaction
- Over 200 million lives eligible to receive ProSomnus OAT covered by medical insurance

% Inc


Commercial payers

\$Inc

 Government insurance: US Medicare, Germany, Netherlands, UK, etc.



AI-Enhanced Manufacturing Enables Differentiation & Scalability






Experienced Management Team

Experienced industry executives with a strong track record of commercializing novel products









Website: <u>https://investors.prosomnus.com/</u> Email: investors@prosomnus.com

Contacts

Email: investors@prosomnus.com Company Contact: <u>bdow@prosomnus.com</u> Investor Relations: mike.cavanaugh@westwicke.com



Appendix: Clinical Study Citations

Study Name	Sample Size	Classification	Key Finding	Reference
Military 3	360	Independent	Improved Quality of Life	US Army Public Health Center Report: Obstructive Sleep Apnea Surveillance and Oral Appliance Therapy Evaluation, Active Duty U.S. Army, 2014–2019, May 2022
Military 1	288	Independent	88.1% success for all severities	Knowles S, Dekow M, Williamson ML. Oral Appliances for OSA Treatment: Meeting the Quadruple Aim. Mil Med. 2021 Aug 19:usab316. doi: 10.1093/milmed/usab316. Epub ahead of print. PMID: 34411239.
San Diego Registry	211	Independent	AHI and ESS Improved	Rohatgi R. Is the Relationship Between OAT Outcomes, Dosage and OAT Device Type as Expected? A Private Practice, Retrospective Cohort Study. Journal of Dental Sleep Medicine. Vol. 6, No.3 2019. Abstract #030.
Syracuse	115	Independent	91% success for mild/moderate	Sall E. Precision Oral Appliance Therapy: The Prime-Time Treatment for OSA. World Sleep Congress. Rome, Italy. Poster Abstract #289. March 2022.
NOTUS3	58	Independent	94% success for mild/moderate	Mosca EV, Bruehlmann S, Zouboules SM, et al. In-home mandibular repositioning during sleep using MATRx plus predicts outcome and efficacious positioning for oral appliance treatment of obstructive sleep apnea. J Clin Sleep Med. 2022;18(3):911–919.
Multi-Center	55	Company Supported	98% success for mild/moderate	Smith K; Carollo J; Desai A; Murphy M. Efficacy of a Novel Precision Iterative Device and Material. World Sleep Congress. Rome, Italy. Poster Abstract #081. March 2022.
Detroit Registry	50	Independent	92% success for mild/moderate	Murphy M, Munro K. Device Design's Impact on Dose in Oral Appliance Therapy. Journal of Dental Sleep Medicine. Vol. 8, No. 3 2021. Abstract #004.
NOTUS2	48	Independent	90% success for mild/moderate	Remmers JE, Topor Z, Grosse J, Vranjes N, Mosca EV, Brant R, Bruehlmann S, Charkhandeh S, Zareian Jahromi SA. A Feedback-Controlled Mandibular Positioner Identifies Individuals With Sleep Apnea Who Will Respond to Oral Appliance Therapy. J Clin Sleep Med. 2017 Jul 15;13(7):871-880. doi: 10.5664/jcsm.6656. PMID: 28502280; PMCID: PMC5482578.
Multicenter preference	31	Company Supported	100% preferred	Elliott E, Ehtessabian J, Murphy M, Rein J, Seltzer N, Schwartz D, Shah S, Smith K. A Multi-Center Preference study of a Novel Oral Appliance Design and Material for Better Provider, Physician, Patient and Payer Acceptance. SLEEP Journal. Vol. 44, Abstract Supplement, 2021. Abstract #440. Page A 174.
EFFECTS Study	28	Company Supported	93.6% compliance	Stern J, Lee K, Kuhns D, et al. (June 02, 2021) Efficacy and Effectiveness of the ProSomnus® [IA] Sleep Device for the Treatment of Obstructive Sleep Apnea: EFFECTS Study. Cureus 13(6): e15391. DOI 10.7759/cureus.15391
Alaska 3	26	Independent	62% improvement	Hu JC, Comisi JC. Vertical dimension in dental sleep medicine oral appliance therapy. Gen Dent. 2020 Jul- Aug;68(4):69-76. PMID: 32597782.
Military 2	24	Independent	87.5% success for all severities	Kang CRS, Knowles S, Dekow M. The Success of Oral Appliance Therapy Based on Symptom-Driven Titration. Mil Med. 2022 Aug 20:usac248. doi: 10.1093/milmed/usac248. Epub ahead of print. PMID: 35986605.
Carlton Study	20	Independent	75% improvement	Carlton D, Is Selecting the Appropriate Sleep Device Important for You and Your Patient Important? Dental Sleep Practice, Summer 2016.
UoP	18	Independent	No change in teeth/bite	Vranjes N, Santucci G, Schulze K, Kuhns D, Khai A. Assessment of potential tooth movement and bite changes with a hard-acrylic sleep appliance: A 2-year clinical study. J Dent Sleep Med. 2019;6(2)
India	10	Independent	No change in teeth/bite	Aziz R, Somaiah S, Kalha AS, Reddy G, Muddaiah S, Shetty B. Comparative assessment of changes in pharyngeal airway space in cases of obstructive sleep apnoea with a customized mandibular repositioning appliance - a clinical study. Sleep Sci. 2021 Jan-Mar;14(Spec1):16-24. doi: 10.5935/1984-0063.20200072. PMID: 34917269; PMCID: PMC8663729.
Alaska 2	8	Company Supported	87.9% compliance	Hu J, Liptak L. Evaluation of a new oral appliance with objective compliance recording capability: a feasibility study. Journal of Dental Sleep Medicine. 2018;5(2):47–50.
Alaska 1	7	Company Supported	71% improvement	Hu et al, Dental Sleep Practice, March 2015.
Syracuse	91	Company Supported	89% success all severities (AHI<10)	Sall E, Smith K, Desai A, et al. (December 07, 2023) Evaluating the Clinical Performance of a Novel, Precision Oral Appliance Therapy Medical Device Made Wholly From a Medical Grade Class VI Material for the Treatment of Obstructive Sleep Apnea. Cureus 15(12): e50107. doi:10.7759/cureus.50107
Total Patients	1,448			

